Therapeutic use of omega-3 fatty acids in bipolar disorder

Expert Review of Neurotherapeutics

Volumn 11, Issue 7, 2011, Pages 1029-1047

  Balanzá Martínez, Vicent ^a,b,c   Fries, Gabriel R ^c   Colpo, Gabriela D ^c   Silveira, Patricia P ^c   Portella, André K ^c   Tabarés Seisdedos, Rafael ^a   Kapczinski, Flávio ^c  

^a UNIVERSITY OF VALENCIA   (Spain)

^b HOSPITAL UNIVERSITARIO DR PESET   (Spain)

^c HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

BDNF; bipolar disorder; DHA; EPA; fish oil; lipids; neurogenesis; neuroprotection; neurotrophins; omega 3 fatty acids

Indexed keywords

ARACHIDONIC ACID; BRAIN DERIVED NEUROTROPHIC FACTOR; DOCASAPENTAENOIC ACID; DOCOSAHEXAENOIC ACID; ETHYLEICOSAPENTAENOIC ACID; FISH OIL; ICOSAPENTAENOIC ACID; LINOLENIC ACID; LONG CHAIN FATTY ACID; NEUROTROPHIN; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; PLACEBO; UNCLASSIFIED DRUG;

AGGRESSION; ALZHEIMER DISEASE; ANTIOXIDANT ACTIVITY; BIPOLAR DEPRESSION; BIPOLAR DISORDER; BRAIN DEVELOPMENT; BRAIN FUNCTION; BRAIN NERVE CELL; CELL MEMBRANE; CELL MEMBRANE FLUIDITY; DEPRESSION; DIETARY INTAKE; DOPAMINERGIC SYSTEM; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; FATTY ACID SYNTHESIS; HUMAN; LOCOMOTION; MAJOR DEPRESSION; MOOD DISORDER; NERVE CELL PLASTICITY; NERVOUS SYSTEM DEVELOPMENT; NEUROPROTECTION; NEUROTRANSMISSION; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; STRESS; TREATMENT RESPONSE;

ANIMALS; BIPOLAR DISORDER; BRAIN-DERIVED NEUROTROPHIC FACTOR; FATTY ACIDS, OMEGA-3; HUMANS; NEUROPROTECTIVE AGENTS;

EID: 79959930574     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.11.42     Document Type: Review

References (218)

1. Bowden CL. Bipolar pathophysiology and development of improved treatments. Brain Res. 1235, 92-97 (2008).
2. Soreca I, Frank E, Kupfer DJ. The phenomenology of bipolar disorder: what drives the high rate of medical burden and determines long-term prognosis? Depress. Anxiety 26(1), 73-82 (2009).
3. Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 349, 1436-1442 (1997). (Pubitemid 27212192)
4. Kleinman L, Lowin A, Flood E, Gandhi G, Edgell E, Revicki D. Costs of bipolar disorder. Pharmacoeconomics 21(9), 601-622 (2003). (Pubitemid 36808214)
5. Kapczinski F, Vieta E, Andreazza AC et al. Allostatic load in bipolar disorder: implications for pathophysiology and treatment. Neurosci. Biobehav. Rev. 32(4), 675-692 (2008).
6. Sanchez-Moreno J, Martinez-Aran A, Tabarés-Seisdedos R, Torrent C, Vieta E, Ayuso-Mateos JL. Functioning and disability in bipolar disorder: an extensive review. Psychother. Psychosom. 78(5), 285-297 (2009).
7. Tabarés-Seisdedos R, Balanzá-Martínez V, Sánchez-Moreno J et al. Neurocognitive and clinical predictors of functional outcome in patients with schizophrenia and bipolar I disorder at one-year follow-up. J. Affect. Disord. 109, 286-299 (2008).
8. Wingo AP, Harvey PD, Baldessarini RJ. Neurocognitive impairment in bipolar disorder patients: functional implications. Bipolar Disord. 11, 113-125 (2009).
9. Carney CP, Jones LE. Medical comorbidity in women and men with bipolar disorders: A population-based controlled study. Psychosom. Med. 68, 684-691 (2006). (Pubitemid 44454636)
10. McIntyre RS, Soczynska JK, Beyer JL et al. Medical comorbidity in bipolar disorder: re-prioritizing unmet needs. Curr. Opin. Psychiatry 20(4), 406-416 (2007). (Pubitemid 46889670)
11. Fiedorowicz JG, Palagummi NM, Forman-Hoffman VL, Miller DD, Haynes WG. Elevated prevalence of obesity, metabolic syndrome, and cardiovascular risk factors in bipolar disorder. Ann. Clin. Psychiatry 20(3), 131-137 (2008). (Pubitemid 352009283)
12. McIntyre RS, Konarski JZ, Soczynska JK et al. Medical comorbidity in bipolar disorder: implications for functional outcomes and health service utilization. Psychiatr. Serv. 57, 1140-1144 (2006 (Pubitemid 44204907)
13. Fagiolini A, Kupfer DJ, Houck PR, Novick DM, Frank E. Obesity as a correlate of outcome in patients with bipolar I disorder. Am. J. Psychiatry 160(1), 112-117 (2003). (Pubitemid 36042434)
14. Youdim KA, Martin A, Joseph JA. Essential fatty acids and the brain: possible health implications. Int. J. Dev. Neurosci. 18(4/5), 383-399 (2000). (Pubitemid 30244351)
15. Kim HY. Novel metabolism of docosahexaenoic acid in neural cells. J. Biol. Chem. 282, 18661-18665 (2007).
16. Fedorova I, Salem Jr N. Omega-3 fatty acids and rodent behavior. Prostaglandins Leukot. Essent. Fatty Acids 75(4-5), 271-289 (2006). (Pubitemid 44444990)
17. Martins JG. EPA but not DHA appears to be responsible for the efficacy of omega-3 long chain polyunsaturated fatty acid supplementation in depression: evidence from a meta-analysis of randomized controlled trials. J. Am. Coll. Nutr. 28(5), 525-542 (2009).
18. Appleton KM, Rogers PJ, Ness AR. Updated systematic review and meta-analysis of the effects of n-3 long-chain polyunsaturated fatty acids on depressed mood. Am. J. Clin. Nutr. 91(3), 757-770 (2010).
19. Rocha Araujo DM, Vilarim MM, Nardi AE. What is the effectiveness of the use of polyunsaturated fatty acid omega-3 in the treatment of depression? Expert Rev. Neurother. 10(7), 1117-1129 (2010).
20. Wu A, Ying Z, Gomez-Pinilla F. Dietary omega-3 fatty acids normalize BDNF levels, reduce oxidative damage, and counteract learning disability after traumatic brain injury in rats. J. Neurotrauma 21, 1457-1467 (2004). (Pubitemid 39435321)
21. Rao JS, Ertley RN, Lee HJ et al. n-3 polyunsaturated fatty acid deprivation in rats decreases frontal cortex BDNF via a p38 MAPK-dependent mechanism. Mol. Psychiatry 12, 36-46 (2007). (Pubitemid 44973661)
22. Post RM. Kindling and sensitization as models for affective episode recurrence, cyclicity, and tolerance phenomena. Neurosci. Biobehav. Rev. 31(6), 858-873 (2007). (Pubitemid 47285350)
23. Kapczinski F, Frey BN, Kauer-SantAnna M, Grassi-Oliveira R. Brain-derived neurotrophic factor and neuroplasticity in bipolar disorder. Expert Rev. Neurother. 8(7), 1101-1113 (2008). (Pubitemid 351962077)
24. Shimizu E, Hashimoto K, Okamura N, et al. Alterations of serum levels of brainderived neurotrophic factor (BDNF) in depressed patients with or without antidepressants. Biol. Psychiatry 54, 70-75 (2003). (Pubitemid 36776725)
25. Fukumoto T, Morinobu S, Okamoto Y, Kagaya A, Yamawaki S. Chronic lithium treatment increases the expression of brain-derived neurotrophic factor in the rat brain. Psychopharmacology (Berl.) 158(1), 100-106 (2001).
26. Li N, He X, Qi X, Zhang Y, He S. The mood stabilizer lamotrigine produces antidepressant behavioral effects in rats: role of brain-derived neurotrophic factor. J. Psychopharmacol. 24(12), 1772-1778 (2010).
27. de Oliveira GS, Ceresér KM, Fernandes BS, et al. Decreased brain-derived neurotrophic factor in medicated and drug-free bipolar patients. J. Psychiatr. Res. 43(14), 1171-1174 (2009).
28. Logan AC. Neurobehavioral aspects of omega-3 fatty acids: possible mechanisms and therapeutic value in major depression. Altern. Med. Rev. 8(4), 410-425 (2003 (Pubitemid 37493870)
29. Rao JS, Ertley RN, DeMar JC Jr, Rapoport SI, Bazinet RP, Lee HJ. Dietary n-3 PUFA deprivation alters expression of enzymes of the arachidonic and docosahexaenoic acid cascades in rat frontal cortex. Mol. Psychiatry. 12, 151-157 (2007). (Pubitemid 46160980)
30. Levant B, Ozias MK, Davis PF et al. Decreased brain docosahexaenoic acid content produces neurobiological effects associated with depression: interactions with reproductive status in female rats. Psychoneuroendocrinology 33, 1279-1292 (2008).
31. Stoll AL, Locke CA, Marangell LB, Severus WE. Omega-3 fatty acids and bipolar disorder: a review. Prostaglandins Leukot. Essent. Fatty Acids 60, 329-337 (1999). (Pubitemid 29401788)
32. Emken EA, Adlof RO, Gulley RM. Dietary linoleic acid influences desaturation and acylation of deuterium-labeled linoleic and linolenic acids in young adult males. Biochim. Biophys. Acta 1213, 277-288 (1994). (Pubitemid 24262911)
33. Goyens PL, Spilker ME, Zock PL, Katan MB, Mensink RP. Compartmental modeling to quantify a-linolenic acid conversion after longer term intake of multiple tracer boluses. J. Lipid Res. 46, 1474-1483 (2005). (Pubitemid 43109812)
34. Bezard J, Blond JP, Bernard A, Clouet P. The metabolism and availability of essential fatty acids in animal abd human tissues. Reprod. Nutr. Dev. 34, 539-568 (1994).
35. Nakamura MT, Nara TY. Structure, function and dietary regulation of d-6, d-5 and d-9 desaturases. Annu. Rev. Nutr. 24(4), 345-376 (2004).
36. Smith WL. Prostanoid biosynthesis and mechanism of action. Am. J. Physiol. Renal Physiol. 263(2 Pt 2), F181-F191 (1992).
37. Simopoulos AP. Omega-6/omega-3 essential fatty acid ratio and chronic diseases. Food Rev. Int. 20(1), 77-90 (2004). (Pubitemid 38474536)
38. Sastry PS. Lipids of nervous tissue: composition and metabolism. Prog. Lipid Res. 242, 69-176 (1985).
39. Kim HY, Akbar M, Kim YS. Phosphatidylserine-dependent neuroprotective signaling promoted by docosahexaenoic acid. Prostaglandins Leukot. Essent. Fatty Acids 82(4-6), 165-172 (2010).
40. Ouellet M, Emond V, Chen CT et al. Diffusion of docosahexaenoic and eicosapentaenoic acids through the blood-brain barrier: an in situ cerebral perfusion study. Neurochem. Int. 55(7), 476-482 (2009).
41. Dobbing J, Sands J. Comparative aspects of the brain growth spurt. Early Hum. Dev. 31, 79-83 (1979). (Pubitemid 9141710)
42. Martinez M. Tissue levels of polyunsaturated fatty acids during early human development. J. Pediatr. 1204(Pt 2), S129-S138 (1992).
43. Williams CM, Burdge G. Long-chain n-3 PUFA: plant v. marine sources. Proc. Nutr. Soc. 651, 42-50 (2006). (Pubitemid 43259983)
44. Su H. Mechanisms of n-3 fatty acid-mediated development and maintenance of learning memory performance. J. Nutr. Biochem. 21, 364-373 (2010).
45. Bourre JM, Dumont O, Durand G. Brain phospholipids as dietary source of (n-3) polyunsaturated fatty acids for nervous tissue in the rat. J. Neurochem. 60, 2018-2028 (1993). (Pubitemid 23148773)
46. Cunnane SC, Francescutti V, Brenna JT, Crawford MA. Breast-fed infants achieve a higher rate of brain and whole body docosahexaenoate accumulation than formula-fed infants not consuming dietary docosahexaenoate. Lipids 35(1), 105-111 (2000). (Pubitemid 30084637)
47. Aid S, Vancassel S, Poumes-Ballihaut C, Chalon S, Guesnet P, Lavialle M. Effect of a diet-induced n-3 PUFA depletion on cholinergic parameters in the rat hippocampus. J. Lipid Res. 44(8), 1545-1551 (2003). (Pubitemid 37279599)
48. Chalon S. Omega-3 fatty acids and monoamine neurotransmission. Prostaglandins Leukot. Essent. Fatty Acids 75(4-5), 259-269 (2006). (Pubitemid 44442912)
49. Alessandri JM, Guesnet P, Vancassel S et al. Polyunsaturated fatty acids in the central nervous system: evolution of concepts and nutritional implications throughout life. Reprod. Nutr. Dev. 44(6), 509-538 (2004). (Pubitemid 40309154)
50. Hichami A, Datiche F, Ullah S et al. Olfactory discrimination ability and brain expression of c-fos, Gir and Glut1mRNA are altered in n-3 fatty acid-depleted rats. Behav. Brain Res. 184(1), 1-10 (2007). (Pubitemid 47404648)
51. Innis SM. Dietary omega 3 fatty acids and the developing brain. Brain Res. 1237, 35-43 (2008).
52. Chung WL, Chen JJ, Su HM. Fish oil supplementation of control and (n-3) fatty acid-deficient male rats enhances reference and working memory performance and increases brain regional docosahexaenoic acid levels. J. Nutr. 1386, 1165-1171 (2008).
53. Lim SY, Hoshiba J, Moriguchi T, Salem N Jr. N-3 fatty acid deficiency induced by a modified artificial rearing method leads to poorer performance in spatial learning tasks. Pediatr. Res. 584, 741-748 (2005). (Pubitemid 41368907)
54. Wu A, Ying Z, Gomez-Pinilla F. Docosahexaenoic acid dietary supplementation enhances the effects of exercise on synaptic plasticity and cognition. Neuroscience 155(3), 751-759 (2008).
55. Mizuno K, Giese KP. Hippocampus-dependent memory formation: do memory type-specific mechanisms exist? J. Pharmacol. Sci. 983, 191-197 (2005). (Pubitemid 41296396)
56. Bas O, Songur A, Sahin O et al. The protective effect of fish n-3 fatty acids on cerebral ischemia in rat hippocampus. Neurochem. Int. 503, 548-554 (2007). (Pubitemid 46186606)
57. Umezawa M, Kogishi K, Tojo H et al. High-linoleate and high-a-linolenate diets affect learning ability and natural behavior in samr1 mice. J. Nutr. 129 (2), 431-437 (1999). (Pubitemid 29072132)
58. Levant B, Radel JD, Carlson SE. Decreased brain docosahexaenoic acid during development alters dopamine-related behaviors in adult rats that are differentially affected by dietary remediation. Behav. Brain Res. 152 (1), 49-57 (2004). (Pubitemid 38597063)
59. Vancassel S, Aid S, Pifferi F et al. Cerebral asymmetry and behavioral lateralization in rats chronically lacking n-3 polyunsaturated fatty acids. Biol. Psychiatry 58(10), 805-811 (2005). (Pubitemid 41677419)
60. Lavialle M, Champeil-Potokar G, Alessandri JM, et al. An (n-3) polyunsaturated fatty acid-deficient diet disturbs daily locomotor activity, melatonin rhythm, and striatal dopamine in Syrian hamsters. J. Nutr. 138(9), 1719-1724 (2008).
61. McNamara RK, Sullivan J, Richtand NM et al. Omega-3 fatty acid deficiency augments amphetamine-induced behavioral sensitization in adult DBA/2J mice: relationship with ventral striatum dopamine concentrations. Synapse 62(10), 725-735 (2008).
62. DeMar JC Jr, Ma K, Bell JM, Igarashi M, Greenstein D, Rapoport SI. One generation of n-3 polyunsaturated fatty acid deprivation increases depression and aggression test scores in rats. J. Lipid Res. 47, 172-180 (2006). (Pubitemid 43107460)
63. Hamazaki T, Sawazaki S, Itomura M et al. The effect of docosahexaenoic acid on aggression in young adults. A placebo-controlled double-blind study. J. Clin. Invest. 97(4), 1129-1133 (1996). (Pubitemid 26070593)
64. Takeuchi T, Iwanaga M, Harada E. Possible regulatory mechanism of DHA-induced anti-stress reaction in rats. Brain Res. 964(1), 136-143 (2003). (Pubitemid 36165079)
65. Delion S, Chalon S, Guilloteau D, Besnard JC, Durand G. alinolenic acid dietary deficiency alters age-related changes of dopaminergic and serotoninergic neurotransmission in the rat frontal cortex. J. Neurochem. 66, 1582-1591 (1996).
66. Zimmer L, Hembert S, Durand G, et al. Chronic n-3 polyunsaturated fatty acid diet-deficiency acts on dopamine metabolism in the rat frontal cortex: a microdialysis study. Neurosci. Lett. 240, 177-181 (1998). (Pubitemid 28079051)
67. Zimmer L, Breton P, Durand G, Guilloteau D, Besnard JC, Chalon S. Prominent role of n-3 polyunsaturated fatty acids in cortical dopamine metabolism. Nutr. Neurosci. 2, 257-265 (1999).
68. Zimmer L, Delion-Vancassel S, Durand G et al. Modification of dopamine neurotransmission in the nucleus accumbens of rats deficient in n-3 polyunsaturated fatty acids. J. Lipid Res. 41, 32-40 (2000). (Pubitemid 30051839)
69. Zimmer L, Vancassel S, Cantagrel S et al. The dopamine mesocorticolimbic pathway is affected by deficiency in n-3 polyunsaturated fatty acids. Am. J. Clin. Nutr. 75(4), 662-667 (2002). (Pubitemid 34250678)
70. Levant B, Ozias MK, Carlson SE. Specific brain regions of female rats are differentially depleted of docosahexaenoic acid by reproductive activity and an (n-3) fatty acid-deficient diet. J. Nutr. 137(1), 130-134 (2007). (Pubitemid 46052870)
71. Hamilton L, Greiner R, Salem N Jr, Kim HY. n-3 fatty acid deficiency decreases phosphatidylserine accumulation selectively in neuronal tissues. Lipids 35(8), 863-869 (2000).
72. Garcia MC, Ward G, Ma YC, Salem N Jr, Kim HY. Effect of docosahexaenoic acid on the synthesis of phosphatidylserine in rat brain in microsomes and C6 glioma cells. J. Neurochem. 70(1), 24-30 (1998). (Pubitemid 28020824)
73. Tam O, Innis SM. Dietary polyunsaturated fatty acids in gestation alter fetal cortical phospholipids, fatty acids and phosphatidylserine synthesis. Dev. Neurosci. 28(3), 222-229 (2006).
74. Akbar M, Calderon F, Wen Z, Kim HY. Docosahexaenoic acid: a positive modulator of Akt signaling in neuronal survival. Proc. Natl Acad. Sci. USA 102(31), 10858-10863 (2005). (Pubitemid 41105957)
75. Ximenes da Silva A, Lavialle F, Gendrot G, Guesnet P, Alessandri JM, Lavialle M. Glucose transport and utilization are altered in the brain of rats deficient in n-3 polyunsaturated fatty acids. J. Neurochem. 81, 1328-1337 (2002). (Pubitemid 34809266)
76. Pifferi F, Roux F, Langelier B et al. (n-3) polyunsaturated fatty acid deficiency reduces the expression of both isoforms of the brain glucose transporter GLUT1 in rats. J. Nutr. 135, 2241-2246 (2005). (Pubitemid 41298394)
77. Kuperstein F, Yakubov E, Dinerman P et al. Overexpression of dopamine receptor genes and their products in the postnatal rat brain following maternal n-3 fatty acid dietary deficiency. J. Neurochem. 95(6), 1550-1562 (2005). (Pubitemid 41804053)
78. Kuperstein F, Eilam R, Yavin E. Altered expression of key dopaminergic regulatory proteins in the postnatal brain following perinatal n-3 fatty acid dietary deficiency. J. Neurochem. 106, 662-671 (2008).
79. Ahmad SO, Park JH, Radel JD, Levant B. Reduced numbers of dopamine neurons in the substantia nigra pars compacta and ventral tegmental area of rats fed an n-3 polyunsaturated fatty acid-deficient diet: a stereological study. Neurosci. Lett. 438(3), 303-307 (2008).
80. Weisinger RS, Armitage JA, Chen N et al. Sodium appetite in adult rats following omega-3 polyunsaturated fatty acid deficiency in early development. Appetite 55(3), 393-397 (2010).
81. Begg DP, Sinclair AJ, Stahl LA et al. Hypertension induced by w-3 polyunsaturated fatty acid deficiency is alleviated by a-linolenic acid regardless of dietary source. Hypertens. Res. 33(8), 808-813 (2010).
82. Weisinger HS, Armitage JA, Sinclair AJ, Vingrys AJ, Burns PL, Weisinger RS. Perinatal omega-3 fatty acid deficiency affects blood pressure later in life. Nature Med. 7(3), 258-259 (2001). (Pubitemid 32224317)
83. Begg DP, Sinclair AJ, Stahl LA, Garg ML, Jois M, Weisinger RS. Dietary protein level interacts with omega-3 polyunsaturated fatty acid deficiency to induce hypertension. Am. J. Hypertens. 23(2), 125-128 (2010).
84. Storlien LH, Jenkins AB, Chisholm DJ, Pascoe WS, Khouri S, Kraegen EW. Influence of dietary fat composition on development of insulin resistance in rats. Relationship to muscle triglyceride and omega-3 fatty acids in muscle phospholipid. Diabetes 40(2), 280-289 (1991).
85. Takahashi Y, Ide T. Dietary n-3 fatty acids affect mRNA level of brown adipose tissue uncoupling protein 1, and white adipose tissue leptin and glucose transporter 4 in the rat. Br. J. Nutr. 84(2), 175-184 (2000). (Pubitemid 30670245)
86. Nettleton JA, Katz R. n-3 long-chain polyunsaturated fatty acids in Type 2 diabetes: a review. J. Am. Diet. Assoc. 105(3), 428-440 (2005). (Pubitemid 40326734)
87. Abeywardena MY, Head RJ. Longchain n-3 polyunsaturated fatty acids and blood vessel function. Cardiovasc. Res. 52(3), 361-371 (2001). (Pubitemid 33153099)
88. Das UN. Long-chain polyunsaturated fatty acids interact with nitric oxide superoxide anion, and transforming growth factor-b to prevent human essential hypertension. Eur. J. Clin. Nutr. 58, 195-203 (2004). (Pubitemid 38256571)
89. Hassanali Z, Ametaj BN, Field CJ, Proctor SD, Vine DF. Dietary supplementation of n-3 PUFA reduces weight gain and improves postprandial lipaemia and the associated inflammatory response in the obese JCR:LA-cp rat. Diabetes Obes. Metab. 12(2), 139-147 (2010).
90. Matthews K, Wilkinson LS, Robbins TW. Repeated maternal separation of preweanling rats attenuates behavioral responses to primary and conditioned incentives in adulthood. Physiol. Behav. 59(1), 99-107 (1996). (Pubitemid 26008214)
91. Mathieu G, Denis S, Lavialle M, Vancassel S. Synergistic effects of stress and omega-3 fatty acid deprivation on emotional response and brain lipid composition in adult rats. Prostaglandins Leukot. Essent. Fatty Acids 78(6), 391-401 (2008).
92. Kodas E, Vancassel S, Lejeune B, Guilloteau D, Chalon S. Reversibility of n-3 fatty acid deficiency-induced changes in dopaminergic neurotransmission in rats: critical role of developmental stage. J. Lipid Res. 43(8), 1209-1219 (2002). (Pubitemid 34988169)
93. Lin P-Y, Su K-P. A meta-analytic review of doubleblind, placebo-controlled trials of anti-depressant efficacy of omega-3 fatty acids. J. Clin. Psychiatry 68, 1056-1061 (2007). (Pubitemid 47340326)
94. Ross BM, Seguin J, Sieswerda LE. Omega-3 fatty acids as treatments for mental illness: which disorder and which fatty acid? Lipids Health Dis. 6, 21 (2007).
95. Liperoti R, Landi F, Fusco O, Bernabei R, Onder G. Omega-3 polyunsaturated fatty acids and depression: a review of the evidence. Curr. Pharm. Des. 15(36), 41654172 (2009).
96. McNamara RK. Evaluation of docosahexaenoic acid deficiency as a preventable risk factor for recurrent affective disorders: current status, future directions, and dietary recommendations. Prostaglandins Leukot. Essent. Fatty Acids 81(2-3), 223-231 (2009
97. Noaghiul S, Hibbeln JR. Cross-national comparisons of seafood consumption and rates of bipolar disorders. Am. J. Psychiatry 160, 2222-2227 (2003). (Pubitemid 39619617)
98. Hibbeln JR. Fish consumption and major depression. Lancet 351 (9110), 1213 (1998).
99. Hibbeln JR. Seafood consumption, the DHA content of mothers milk and prevalence rates of postpartum depression: a cross-national, ecological analysis. J. Affect. Disord. 69, 15-29 (2002). (Pubitemid 34722867)
100. Tanskanen A, Hibbeln JR, Tuomilehto J et al. Fish consumption and depressive symptoms in the general population in Finland. Psychiatr. Serv. 52(4), 529-531 (2001). (Pubitemid 32275317)
101. Sanchez-Villegas A, Henríquez P, Figueiras A, Ortuño F, Lahortiga F, Martínez-González MA. Long chain omega-3 fatty acids intake, fish consumption and mental disorders in the SUN cohort study. Eur. J. Nutr. 46(6), 337-346 (2007). (Pubitemid 47353608)
102. Hakkarainen R, Partonen T, Haukka J, Virtamo J, Albanes D, Lönnqvist J. Is low dietary intake of omega-3 fatty acids associated with depression? Am. J. Psychiatry 161(3), 567-569 (2004). (Pubitemid 38326115)
103. Harris WS, Pottala JV, Sands SA, Jones PG. Comparison of the effects of fish and fish-oil capsules on the n 3 fatty acid content of blood cells and plasma phospholipids. Am. J. Clin. Nutr. 86(6), 1621-1625 (2007). (Pubitemid 350232175)
104. Makrides M, Neumann MA, Byard RW, Simmer K, Gibson RA. Fatty acid composition of brain, retina, and erythrocytes in breast- and formula-fed infants. Am. J. Clin. Nutr. 60(2), 189-194 (1994). (Pubitemid 24233184)
105. Chiu CC, Huang SY, Su KP et al. Polyunsaturated fatty acid deficit in patients with bipolar mania. Eur. Neuropsychopharmacol. 13, 99-103 (2003).
106. McNamara RK, Jandacek R, Rider T, Tso P, Dwivedi Y, Pandey GN. Selective deficits in erythrocyte docosahexaenoic acid composition in adult patients with bipolar disorder and major depressive disorder. J. Affect. Disord. 126(1-2), 303-311 (2010).
107. Ranjekar PK, Hinge A, Hegde MV et al. Decreased antioxidant enzymes and membrane essential polyunsaturated fatty acids in schizophrenic and bipolar mood disorder patients. Psychiatry Res. 121, 109-122 (2003). (Pubitemid 37500981)
108. Sublette ME, Bosetti F, DeMar JC, et al. Plasma free polyunsaturated fatty acid levels are associated with symptom severity in acute mania. Bipolar Disord. 9, 759-765 (2007). (Pubitemid 350042412)
109. Sobczak S, Honig A, Christophe A et al. Lower high-density lipoprotein cholesterol and increased omega-6 polyunsaturated fatty acids in first-degree relatives of bipolar patients. Psychol. Med. 34(1), 103-112 (2004). (Pubitemid 38139445)
110. Clayton EH, Hanstock TL, Hirneth SJ, Kable CJ, Garg ML, Hazell PL. Long-chain omega-3 polyunsaturated fatty acids in the blood of children and adolescents with juvenile bipolar disorder. Lipids 43(11), 1031-1038 (2008).
111. Lin PY, Huang SY, Su KP. A meta-analytic review of polyunsaturated fatty acid compositions in patients with depression. Biol. Psychiatry 68(2), 140-147 (2010
112. Appleton KM, Rogers PJ, Ness AR. Is there a role for n-3 long-chain polyunsaturated fatty acids in the regulation of mood and behaviour? A review of the evidence to date from epidemiological studies, clinical studies and intervention trials. Nutr. Res. Rev. 21(1), 13-41 (2008).
113. McNamara RK, Jandacek R, Rider T et al. Deficits in docosahexaenoic acid and associated elevations in the metabolism of arachidonic acid and saturated fatty acids in the postmortem orbitofrontal cortex of patients with bipolar disorder. Psychiatry Res. 160(3), 285-299 (2008).
114. Schwarz E, Prabakaran S, Whitfield P et al. High throughput lipidomic profiling of schizophrenia and bipolar disorder brain tissue reveals alterations of free fatty acids, phosphatidylcholines, and ceramides. J. Proteome Res. 7(10), 4266-4277 (2008).
115. Young G, Conquer J. Omega-3 fatty acids and neuropsychiatric disorders. Reprod. Nutr. Dev. 45(1), 1-28 (2005). (Pubitemid 40528530)
116. Freeman MP, Hibblen JR, Wisner KL et al. Omega-3 fatty acids: evidence basis for treatment and future research in psychiatry. J. Clin. Psychiatry 67, 1954-1967 (2006). (Pubitemid 46048194)
117. Crawford MA, Bazinet RP, Sinclair AJ. Fat intake and CNS functioning: ageing and disease. Ann. Nutr. Metab. 55(1-3), 202-228 (2009).
118. Stoll AL, Severus WE, Freeman MP et al. Omega-3 fatty acids in bipolar disorder a preliminary double-blind, placebo-controlled trial. Arch Gen Psychiatry. 56, 407-412 (1999). (Pubitemid 29215428)
119. Frangou S, Lewis M, McCrone P. Efficacy of ethyleicosapentaenoic acid in bipolar depression: randomized double-blind placebo-controlled study. Br. J. Psychiatry 188, 46-50 (2006). (Pubitemid 43021926)
120. Keck PE Jr, Mintz J, McElroy SL et al. Double-blind, randomized, placebo-controlled trials of ethyl-eicosapentanoate in the treatment of bipolar depression and rapid cycling bipolar disorder. Biol. Psychiatry 60, 1020-1022 (2006). (Pubitemid 44739928)
121. Gracious BL, Chirieac MC, Costescu S, Finucane TL, Youngstrom EA, Hibbeln JR. Randomized, placebo-controlled trial of flax oil in pediatric bipolar disorder. Bipolar Disord. 12(2), 142-154 (2010).
122. Osher Y, Bersudsky Y, Belmaker RH. Omega-3 eicosapentaenoic acid in bipolar depression: report of a small open-label study. J. Clin. Psychiatry 66(6), 726-729 (2005). (Pubitemid 40942418)
123. Sagduyu K, Dokucu ME, Eddy BA, Craigen G, Baldassano CF, Yildiz A. Omega-3 fatty acids decreased irritability of patients with bipolar disorder in an add-on, open label study. Nutr. J. 4, 1-6 (2005).
124. Clayton EH, Hanstock TL, Hirneth SJ, Kable CJ, Garg ML, Hazell PL. Reduced mania and depression in juvenile bipolar disorder associated with long-chain omega-3 polyunsaturated fatty acid supplementation. Eur. J. Clin. Nutr. 63(8), 1037-1040 (2009).
125. Wozniak J, Biederman J, Mick E et al. Omega-3 fatty acid monotherapy for pediatric bipolar disorder: a prospective open-label trial. Eur. Neuropsychopharmacol. 17(6-7), 440-447 (2007). (Pubitemid 46497662)
126. Sinclair AJ, Begg D, Mathai M, Weisinger RS. Omega 3 fatty acids and the brain: review of studies in depression. Asia Pac. J. Clin. Nutr. 16(Suppl. 1), 391-397 (2007). (Pubitemid 46524632)
127. Rao JS, Lee HJ, Rapoport SI, Bazinet RP. Mode of action of mood stabilizers: is the arachidonic acid cascade a common target? Mol. Psychiatry 13(6), 585-596 (2008). (Pubitemid 351704942)
128. Serhan CN, Yacoubian S, Yang R. Anti-inflammatory and proresolving lipid mediators. Annu. Rev. Pathol. 3, 279-312 (2008). (Pubitemid 351488283)
129. Bazan NG. Neuroprotectin D1-mediated anti-inflammatory and survival signaling in stroke, retinal degenerations, and Alzheimers disease. J. Lipid Res. 50(Suppl.) S400-S405 (2009).
130. Kitajka K, Sinclair AJ, Weisinger RS et al. Effects of dietary omega-3 polyunsaturated fatty acids on brain gene expression. Proc. Natl Acad. Sci. USA 101, 10931-10936 (2004). (Pubitemid 38989562)
131. Katsumata T, Katayama Y, Obo R, Muramatsu H, Ohtori T, Terashi A. Delayed administration of ethyl eicosapentate improves local cerebral blood flow and metabolism without affecting infarct volumes in the rat focal ischemic model. Eur. J. Pharmacol. 372(2), 167-174 (1999). (Pubitemid 29251288)
132. Chalon S, Delion-Vancassel D, Belzung C et al. Dietary fish oil affects monoaminergic neurotransmission and behavior in rats. J. Nutr. 128, 2512-2519 (1998). (Pubitemid 29013003)
133. Mitchell DC, Niu SL, Litman BJ. DHA-rich phospholipids optimize G-protein-coupled signaling. J. Pediatr. 143(Suppl.), S80-S86 (2003). (Pubitemid 37346697)
134. Wood JN. Essential fatty acids and their metabolites in signal transduction. Biochem. Soc. Trans. 18, 785-786 (1990). (Pubitemid 20359301)
135. du Bois TM, Deng C, Bell W, Huang XF. Fatty acids differentially affect serotonin receptor and transporter binding in the rat brain. Neuroscience 139, 1397-1403 (2006).
136. Fenton WS, Hibblen J, Knable M. Essential fatty acids, lipid membrane abnormalities and the diagnosis and treatment of schizophrenia. Biol. Psychiatry 47, 8-21 (2000). (Pubitemid 30016075)
137. Cole GM, Frautschy SA. DHA may prevent age-related dementia. J. Nutr. 140(4), 869-874 (2010).
138. Das UN. Folic acid and polyunsaturated fatty acids improve cognitive function and prevent depression, dementia, and Alzheimers disease - but how and why? Prostaglandins Leukot. Essent. Fatty Acids 78(1), 11-19 (2008).
139. Frangou S, Lewis M, Wollard J, Simmons A. Preliminary in vivo evidence of increased N-acetyl-aspartate following eicosapentanoic acid treatment in patients with bipolar disorder. J. Psychopharmacol. 21, 435-439 (2007). (Pubitemid 47077299)
140. Berger GE, Wood SJ, Wellard RM et al. Ethyl-eicosapentaenoic acid in first-episode psychosis. A 1H-MRS study. Neuropsychopharmacology 33(10), 2467-2473 (2008).
141. Lee HJ, Rao JS, Rapoport SI, Bazinet RP. Antimanic therapies target brain arachidonic acid signaling: lessons learned about the regulation of brain fatty acid metabolism. Prostaglandins Leukot. Essent. Fatty Acids 77(5-6), 239-246 (2007). (Pubitemid 350198854)
142. Pruunsild P, Kazantseva A, Aid T, Palm K, Timmusk T. Dissecting the human BDNF locus: bidirectional transcription, complex splicing, and multiple promoters. Genomics 90(3), 397-406 (2007). (Pubitemid 47179877)
143. Pattabiraman PP, Tropea D, Chiaruttini C, Tongiorgi E, Cattaneo A, Domenici L. Neuronal activity regulates the developmental expression and subcellular localization of cortical BDNF mRNA isoforms in vivo. Mol. Cell. Neurosci. 28(3), 556-570 (2005). (Pubitemid 40311858)
144. Chalovich EM, Zhu JH, Caltagarone J, Bowser R, Chu CT. Functional repression of cAMP response element in 6-hydroxydopamine-treated neuronal cells. J. Biol. Chem. 281, 17870-17881 (2006 (Pubitemid 44035586)
145. Finkbeiner S. CREB couples neurotrophin signals to survival messages. Neuron 25, 11-14 (2000). (Pubitemid 30316505)
146. Lessmann V, Gottmann K, Malcangio M. Neurotrophin secretion: current facts and future prospects. Prog. Neurobiol. 69, 341-374 (2003). (Pubitemid 36645053)
147. Hofer M, Pagliusi SR, Hohn A, Leibrock J, Barde YA. Regional distribution of brain-derived neurotrophic factor mRNA in the adult mouse brain. EMBO J. 9(8), 24592464 (1990).
148. Yamada K, Nabeshima T. Brain-derived neurotrophic factor/TrkB signaling in memory processes. J. Pharmacol. Sci. 91(4), 267-270 (2003). (Pubitemid 36581946)
149. Alonso M, Vianna MR, Izquierdo I, Medina JH. Signaling mechanisms mediating BDNF modulation of memory formation in vivo in the hippocampus. Cell Mol. Neurobiol. 22(5-6), 663-674 (2002). (Pubitemid 36169215)
150. Bekinschtein P, Cammarota M, Izquierdo I, Medina JH. BDNF and memory formation and storage. Neuroscientist 14(2), 147-156 (2008).
151. Dias VV, Brissos S, Frey BN, Andreazza AC, Cardoso C, Kapczinski F. Cognitive function and serum levels of brain-derived neurotrophic factor in patients with bipolar disorder. Bipolar Disord. 11(6), 663-671 (2009).
152. Balanzá-Martínez V, Tabarés-Seisdedos R, Selva-Vera G et al. Persistent cognitive dysfunctions in bipolar -I and schizophrenic patients: a 3-year follow-up study. Psychother. Psychosom. 74(2), 113-119 (2005). (Pubitemid 40470264)
153. Martinez-Aran A, Vieta E, Torrent C et al. Functional outcome in bipolar disorder: the role of clinical and cognitive factors. Bipolar Disord. 9, 103-113 (2007). (Pubitemid 46671678)
154. Egan MF, Kojima M, Callicott JH et al. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 112(2), 257-269 (2003). (Pubitemid 36144114)
155. Rybakowski JK, Borkowska A, Skibinska M, Hauser J. Illness-specific association of val66met BDNF polymorphism with performance on Wisconsin Card Sorting Test in bipolar mood disorder. Mol. Psychiatry 11(2), 122-124 (2006). (Pubitemid 43164612)
156. McIntosh AM, Moorhead TW, McKirdy J et al. Temporal grey matter reductions in bipolar disorder are associated with the BDNF Val66Met polymorphism. Mol. Psychiatry 12(10), 902-903 (2007). (Pubitemid 47482703)
157. Cunha AB, Frey BN, Andreazza AC et al. Serum brain-derived neurotrophic factor is decreased in bipolar disorder during depressive and manic episodes. Neurosci. Lett. 398(3), 215-219 (2006). (Pubitemid 43673698)
158. Kauer-SantAnna M, Kapczinski F, Andreazza AC et al. Brain-derived neurotrophic factor and inflammatory markers in patients with early-vs. late-stage bipolar disorder. Int. J. Neuropsychopharmacol. 12(4), 447-458 (2009
159. Tramontina JF, Andreazza AC, Kauer-Santanna M et al. Brain-derived neurotrophic factor serum levels before and after treatment for acute mania. Neurosci. Lett. 452(2), 111-113 (2009).
160. Palomino A, Vallejo-Illarramendi A, González-Pinto A et al. Decreased levels of plasma BDNF in first-episode schizophrenia and bipolar disorder patients. Schizophr. Res. 86 (1-3), 321-322 (2006). (Pubitemid 44234056)
161. Lin P. State-dependent decrease in levels of brain-derived neurotrophic factor in bipolar disorder: a meta-analytic study. Neurosci Lett. 466, 139-143 (2009).
162. Tsaltas E, Kontis D, Boulougouris V et al. Enhancing effects of chronic lithium on memory in the rat. Behav. Brain Res. 177(1), 51-60 (2007). (Pubitemid 46054196)
163. Walz JC, Frey BN, Andreazza AC et al. Effects of lithium and valproate on serum and hippocampal neurotrophin-3 levels in an animal model of mania. J. Psychiatr. Res. 42(5), 416-421 (2008). (Pubitemid 351253581)
164. Rapoport SI. Brain arachidonic and docosahexaenoic acid cascades are selectively altered by drugs, diet and disease. Prostaglandins Leukot. Essent. Fatty Acids 79(3-5), 153-156 (2008).
165. Basselin M, Kim HW, Chen M et al. Lithium modifies brain arachidonic and docosahexaenoic metabolism in rat lipopolysaccharide model of neuroinflammation. J. Lipid Res. 51(5), 1049-1056 (2010).
166. Cole GM, Ma Q, Frautschy SA. Omega-3 fatty acids and dementia. Prostaglandins Leukot. Essent. Fatty Acids 81, 213-221 (2009
167. Kawakita E, Hashimoto M, Shido O. Docosahexaenoic acid promotes neurogenesis in vitro and in vivo. Neuroscience 1393, 991-997 (2006).
168. Beltz BS, Tlusty MF, Benton JL, Sandeman DC. Omega-3 fatty acids upregulate adult neurogenesis. Neurosci. Lett. 415(2), 154-158 (2007). (Pubitemid 46394591)
169. Dyall SC, Michael GJ, Michael-Titus AT. Omega-3 fatty acids reverse age-related decreases in nuclear receptors and increase neurogenesis in old rats. J. Neurosci. Res. 88(10), 2091-2102 (2010).
170. Beck RD Jr, Wasserfall C, Ha GK et al. Changes in hippocampal IL-15, related cytokines, and neurogenesis in IL-2 deficient mice. Brain Res. 1041(2), 223-230 (2005).
171. Grimaldi PA. Fatty acid regulation of gene expression. Curr. Opin. Clin. Nutr. Metab. Care 4(5), 433-437 (2001). (Pubitemid 34755434)
172. Jump DB. Dietary polyunsaturated fatty acids and regulation of gene transcription. Curr. Opin. Lipidol. 13(2), 155-164 (2002). (Pubitemid 34280767)
173. Lapillonne A, Clarke SD, Heird WC. Polyunsaturated fatty acids and gene expression. Curr. Opin. Clin. Nutr. Metab. Care 7(2), 151-156 (2004). (Pubitemid 40340677)
174. Molteni R, Barnard RJ, Ying Z, Roberts CK, Gómez-Pinilla F. A high-fat, refined sugar diet reduces hippocampal brain-derived neurotrophic factor, neuronal plasticity, and learning. Neuroscience 112, 803-814 (2002). (Pubitemid 34667045)
175. Molteni R, Wu A, Vaynman S, Ying Z, Barnard RJ, Gomez-Pinilla F. Exercise reverses the harmful effects of consumption of a high-fat diet on synaptic and behavioral plasticity associated to the action of brain-derived neurotrophic factor. Neuroscience 123, 429-440 (2004). (Pubitemid 38032919)
176. Frey BN, Andreazza AC, Ceresér KM et al. Effects of mood stabilizers on hippocampus BDNF levels in an animal model of mania. Life Sci. 79(3), 281-286 (2006). (Pubitemid 43782552)
177. Blondeau N, Nguemeni C, Debruyne DN et al. Subchronic a-linolenic acid treatment enhances brain plasticity and exerts an antidepressant effect: a versatile potential therapy for stroke. Neuropsychopharmacology 34(12), 2548-2459 (2009).
178. Jiang L, Shi Y, Long Y, Yang Z. The influence of orally administered docosahexaenoic acid on monoamine neurotransmitter, nerve growth factor, and brain-derived neurotrophic factor in aged mice. Pharmaceut. Biol. 47(7), 584-591 (2009).
179. Venna VR, Deplanque D, Allet C, Belarbi K, Hamdane M, Bordet R. PUFA induce antidepressant-like effects in parallel to structural and molecular changes in the hippocampus. Psychoneuroendocrinology 34(2), 199-211 (2009).
180. Berk M, Conus P, Kapczinski F et al. From neuroprogression to neuroprotection: implications for clinical care. Med. J. Aust. 193(4 Suppl.), S36- S40 (2010).
181. Darmon N, Drewnowski A. Does social class predict diet quality? Am. J. Clin. Nutr. 87(5), 1107-1117 (2008). (Pubitemid 351679745)
182. Medina JM, Tabernero A. Astrocyte-synthesized oleic acid behaves as a neurotrophic factor for neurons. J. Physiol. Paris 96(3-4), 265-271 (2002). (Pubitemid 36090364)
183. Montgomery P, Richardson AJ. Omega-3 fatty acids for bipolar disorder. Cochrane Database Syst. Rev. 2, CD005169 (2008).
184. Huang SY, Yang HT, Chiu CC, Pariante CM, Su KP. Omega-3 fatty acids on the forced-swimming test. J. Psychiatr. Res. 42(1), 58-63 (2008). (Pubitemid 47562432)
185. Cousins DA, Butts K, Young AH. The role of dopamine in bipolar disorder. Bipolar Disord. 11(8), 787-806 (2009).
186. Konarski JZ, McIntyre RS, Kennedy SH, Rafi-Tari S, Soczynska JK, Ketter TA. Volumetric neuroimaging investigations in mood disorders: bipolar disorder versus major depressive disorder. Bipolar Disord. 10(1), 1-37 (2008).
187. Blumberg HP, Leung HC, Skudlarski P et al. A functional magnetic resonance imaging study of bipolar disorder: state-and trait-related dysfunction in ventral prefrontal cortices. Arch. Gen. Psychiatry. 60(6), 601-609 (2003). (Pubitemid 36682317)
188. Sher L, Carballo JJ, Grunebaum MF et al. A prospective study of the association of cerebrospinal fluid monoamine metabolite levels with lethality of suicide attempts in patients with bipolar disorder. Bipolar Disord. 8(5 Pt 2), 543-550 (2006). (Pubitemid 44567136)
189. Gerner RH, Fairbanks L, Anderson GM et al. CSF neurochemistry in depressed, manic, and schizophrenic patients compared with that of normal controls. Am. J. Psychiatry 141(12), 1533-1540 (1984). (Pubitemid 15219750)
190. Sethom MM, Fares S, Bouaziz N et al. Polyunsaturated fatty acids deficits are associated with psychotic state and negative symptoms in patients with schizophrenia. Prostaglandins Leukot. Essent. Fatty Acids 83(3), 131-136 (2010).
191. Marchioli R, Barzi F, Bomba E et al. GISSI-Prevenzione Investigators. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nellInfarto Miocardico (GISSI)-Prevenzione. Circulation 105(16), 1897-1903 (2002). (Pubitemid 34437615)
192. Jicha GA, Markesbery WR. Omega-3 fatty acids: potential role in the management of early Alzheimers disease. Clin. Interv. Aging 5, 45-61 (2010).
193. Berk M, Hallam KT, McGorry PD. The potential utility of a staging model as a course specifier: a bipolar disorder perspective. J. Affect. Disord. 100, 279-281 (2007). (Pubitemid 46818451)
194. Kapczinski F, Dias VV, Kauer- SantAnna M et al. Clinical implications of a staging model for bipolar disorders. Expert Rev. Neurother. 9, 957-966 (2009).
195. Su KP, Huang SY, Peng CY et al. Phospholipase A2 and cyclooxygenase 2 genes influence the risk of interferon-a-induced depression by regulating polyunsaturated fatty acids levels. Biol. Psychiatry 67(6), 550-557 (2010).
196. Xie L, Innis SM. Genetic variants of the FADS1 FADS2 gene cluster are associated with altered (n-6) and (n-3) essential fatty acids in plasma and erythrocyte phospholipids in women during pregnancy and in breast milk during lactation. J. Nutr. 138(11), 2222-2228 (2008).
197. Schaeffer L, Gohlke H, Müller M et al. Common genetic variants of the FADS1 FADS2 gene cluster and their reconstructed haplotypes are associated with the fatty acid composition in phospholipids. Hum. Mol. Genet. 15(11), 1745-1756 (2006). (Pubitemid 43821765)
198. Fallin MD, Lasseter VK, Wolyniec PS et al. Genomewide linkage scan for bipolar-disorder susceptibility loci among Ashkenazi Jewish families. Am. J. Hum. Genet. 75(2), 204-219 (2004). (Pubitemid 38943864)
199. Sontrop J, Campbell MK. n-3 Polyunsaturated fatty acids and depression: a review of the evidence and a methodological critique. Prev. Med. 42, 4-13 (2006). (Pubitemid 43148942)
200. Liu Y, McNamara RK. Elevated d-6 desaturase (FADS2) gene expression in the prefrontal cortex of patients with bipolar disorder. J. Psychiatr. Res. 45, 269-272 (2011).
201. Horrobin DF, Bennett CN. Depression and bipolar disorder: relationships to impaired fatty acid and phospholipid metabolism and to diabetes, cardiovascular disease, immunological abnormalities, cancer, ageing and osteoporosis. Possible candidate genes. Prostaglandins Leukot. Essent. Fatty Acids 60, 217-234 (1999). (Pubitemid 29306598)
202. Milte CM, Sinn N, Howe PR. Polyunsaturated fatty acid status in attention deficit hyperactivity disorder, depression, and Alzheimers disease: towards an omega-3 index for mental health? Nutr. Rev. 67(10), 573-590 (2009).
203. Harris WS, Von Schacky C. The Omega-3 Index: a new risk factor for death from coronary heart disease? Prev. Med. 39(1), 212-220 (2004). (Pubitemid 38797975)
204. Rizzo AM, Montorfano G, Negroni M et al. A rapid method for determining arachidonic:eicosapentaenoic acid ratios in whole blood lipids: correlation with erythrocyte membrane ratios and validation in a large Italian population of various ages and pathologies. Lipids Health Dis. 9, 7 (2010).
205. Connor SL, Zhu N, Anderson GJ et al. Cheek cell phospholipids in human infants: a marker of docosahexaenoic and arachidonic acids in the diet, plasma, and red blood cells. Am. J. Clin. Nutr. 71(1), 21-27 (2000). (Pubitemid 30033580)
206. Kirby A, Woodward A, Jackson S, Wang Y, Crawford MA. The association of fatty acid deficiency symptoms (FADS) with actual essential fatty acid status in cheek cells. Prostaglandins Leukot. Essent. Fatty Acids 83(1), 1-8 (2010).
207. Slagsvold JE, Thorstensen K, Kvitland M et al. Fatty acid desaturase expression in human leukocytes correlates with plasma phopholipid fatty acid status. Scand. J. Clin. Lab. Invest. 69(4), 496-504 (2009).
208. Wall R, Ross RP, Fitzgerald GF, Stanton C. Fatty acids from fish: the antiinflammatory potential of long-chain omega-3 fatty acids. Nutr. Rev. 68(5), 280-289 (2010).
209. He K, Liu K, Daviglus ML et al. Associations of dietary long-chain n-3 polyunsaturated fatty acids and fish with biomarkers of inflammation and endothelial activation (from the Multi- Ethnic Study of Atherosclerosis [MESA]). Am. J. Cardiol. 103(9), 1238-1243 (2009).
210. Galli C, Calder PC. Effects of fat and fatty acid intake on inflammatory and immune responses: a critical review. Ann. Nutr. Metab. 55(1-3), 123-139 (2009
211. Robinson LE, Buchholz AC, Mazurak VC. Inflammation, obesity, and fatty acid metabolism: influence of n-3 polyunsaturated fatty acids on factors contributing to metabolic syndrome. Appl. Physiol. Nutr. Metab. 32(6), 1008-1024 (2007).
212. Chang JPC, Chen YT, Su KP. Hypothesis: omega-3 polyunsaturated fatty acids (n-3 PUFAs) in cardiovascular diseases (CVD) and depression: the missing link? Cardiovasc. Psychiatry Neurol. 2009, 725310 (2009).
213. Kapczinski F, Dal-Pizzol F, Teixeira AL et al. A systemic toxicity index developed to assess peripheral changes in mood episodes. Mol. Psychiatry 15(8), 784786 (2010).
214. Gottesman II, Gould TD. The endophenotype concept in psychiatry: etymology and strategic intentions. Am. J. Psychiatry 160(4), 636-645 (2003). (Pubitemid 41079594)
215. Amminger GP, Schfer MR, Papageorgiou K et al. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch. Gen. Psychiatry 67(2), 146-154 (2010
216. Wu A, Ying Z, Gomez-Pinilla F. Docosahexaenoic acid dietary supplementation enhances the effects of exercise on synaptic plasticity and cognition. Neuroscience 1553, 751-759 (2008).
217. Ruxton CHS, Derbyshire E. Latest evidence on omega-3 fatty acids and health. Nutr. Food Sci. 39(4), 423-438 (2009).
218. Eritsland J. Safety considerations of polyunsaturated fatty acids. Am. J. Clin. Nutr. 71(1 Suppl.), S197-S201 (2000